Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| RWGHK-100-1001 | Nov 2025 | 99.8% | Freedom Diagnostics | Endotoxin | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Riptide Wellness sell GHK-Cu?
Riptide Wellness has 1 COA on file for GHK-Cu but no active price listing is currently tracked.
Is Riptide Wellness's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Riptide Wellness's GHK-Cu, with the most recent showing 99.8% purity. Riptide Wellness holds an overall trust grade of B (84/100) across all 35 COAs on file.
What is Riptide Wellness's trust grade for GHK-Cu?
Riptide Wellness has an overall Disclosed Labs trust grade of B (84/100), computed from 35 COAs across all peptides. The most recent GHK-Cu COA was issued by Freedom Diagnostics.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with Riptide Wellness's listing. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs